title: [Pediatric ependymomas: Current diagnosis and therapy].
abstract: Ependymomas represent 10% of pediatric brain tumors. In the recent WHO 2016 classification, pathology is enriched by localization and molecular biology. Whatever the age, total removal by one or several looks when required remains a major prognostic factor. In children, focal radiation remains a standard, while the role of chemotherapy is matter of randomized studies. In infants, front line chemotherapy is the standard. Inclusion in the SIOP ependymoma II protocol is encouraged. In case of relapse, further surgery and radiation are advised, while inclusion in innovative trials including re-irradiation, and phase I-II should be encouraged. A better understanding of underlying mechanisms of ependymoma cell will provide in the close future, the key to use targeted therapies at time of relapse, and very soon as first line therapy for some subgroups of patients.
authors.affiliation: Centre Léon-Bérard, institut d'hématologie et oncologie pédiatrique, département de neuro-oncologie, place Professeur-Joseph-Renaut, 69008 Lyon, France. Electronic address: didier.frappaz@lyon.unicancer.fr.
authors.forename: Didier
authors.initials: D
authors.lastname: Frappaz
authors.affiliation: Hospices civils de Lyon, département d'anatomopathologie, 59, boulevard Pinel, 69677 Bron cedex, France.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Vasiljevic
authors.affiliation: Hospices civils de Lyon, département de neurochirurgie pédiatrique, 59, boulevard Pinel, 69677 Bron cedex, France.
authors.forename: Pierre-Aurelien
authors.initials: PA
authors.lastname: Beuriat
authors.affiliation: Institut Curie, département de radiothérapie, 26, rue d'Ulm, 75005 Paris, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Alapetite
authors.affiliation: Département de pédiatrie, Gustave Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
authors.forename: Jacques
authors.initials: J
authors.lastname: Grill
authors.affiliation: Hospices civils de Lyon, département de neurochirurgie pédiatrique, 59, boulevard Pinel, 69677 Bron cedex, France.
authors.forename: Alexandru
authors.initials: A
authors.lastname: Szathmari
authors.affiliation: Centre Léon-Bérard, institut d'hématologie et oncologie pédiatrique, département de neuro-oncologie, place Professeur-Joseph-Renaut, 69008 Lyon, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Faure-Conter
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D002648:Child; D004806:Ependymoma / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007223:Infant; D002955:Leucovorin / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D035583:Rare Diseases / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D011344:Procarbazine; D014750:Vincristine; D002955:Leucovorin; D008727:Methotrexate
keywords: Biologie moléculaire; Chemotherapy; Chimiothérapie; Chirurgie; Ependymoma; Molecular biology; Radiotherapy; Radiothérapie; Surgery; Épendymome